Febraayo 2024: Dhowr daawo oo cusub iyo daawayn rajo leh, sida chimeric antigen receptor T-cell therapy, waxay keeneen "dib u soo noolayn" lupus, sida laga soo xigtay af-hayeenka dood-cilmiyeedka Aasaasiga ah iyo Immunology Clinical ee Busy Clinic.
Marka loo eego Emily Littlejohn, DO, MPH, oo ka tirsan Kiliniga Cleveland, unugyada difaaca jirka ee monoclonal iyo interferon waa laba daawayn oo dheeraad ah oo suurtagal ah oo loogu talagalay lupus erythematosus ee soo baxay ilaa 2020.
"2020 waa waxa in badan oo naga mid ah u tixgeliyo dib u soo kabashada lupus," Littlejohn ayaa u sheegay ka qaybgalayaasha intii lagu jiray kulanka isku-dhafka ah. "Tani waa wakhti, ugu dambeyntii, aan helnay daroogo badan oo si degdeg ah u soo galaya hubka."
Waxaa laga yaabaa inaad jeceshahay inaad akhriso: Daaweynta CAR T Cell ee Shiinaha
Sida laga soo xigtay Littlejohn, waxaa jiray daaweyno cusub oo xiiso leh oo loogu talagalay SLE tan iyo markii la ansixiyay degdegga ah ee belimumab (Benlysta, GSK), voclosporin (Lupkynis, Aurinia), iyo anifrolumab (Saphnelo, AstraZeneca). Daaweynta CAR T-cell waxay noqon kartaa kuwa ugu xiisaha badan.
"Tani waxaa loo isticmaalaa adduunka oncology-waxaan ku aragnay [B-cell acute lymphoblastic leukemia], [B-cell non-Hodgkin's lymphoma] iyo mantel cell lymphoma," ayuu yiri Littlejohn. "Su'aashu waxay tahay: Ka waran cuduradayada?"
Littlejohn wuxuu sheegay in dhammaan bukaannada ka qaybqaatay daraasad Jarmal ah oo diiwaangashan shan bukaan oo leh xubno badan oo ka mid ah xubnaha ay awoodaan inay gaaraan xaalad nephritis ay joogsatay. Littlejohn wuxuu intaa ku daray in natiijadu ay rajo ka bixiso, laakiin daawadu maaha mid khatar ah.
Waxaa laga yaabaa inaad jeceshahay inaad akhriso: CAR T daawaynta unugga ee myeloma badan ee Shiinaha
"Waxaa jirta khatar aad u weyn oo ah cilladda sii deynta cytokine - gaar ahaan ICANS - taas oo aad u cabsi badan," ayay tiri.
"Waxaan u maleynayaa inay jiraan ballanqaadyo badan oo goobtan ah, kaliya tixgelinta shantan bukaan [oo lagu daaweeyay daaweynta unugyada CAR-T] iyo sida wanaagsan ee ay u sameeyeen," ayay raacisay.
Beddelka CAR T-cell daaweynta horumar ayay ku jiraan. Kuwaas waxaa ka mid ah litifilimab (BIIB059, Biogen), interferon-kinoid, obinutuzumab (Gazyva, Genentech) iyo iberdomide (Bristol Myers Squibb).
Interferon-kinoid waxay ku guul darreysatay inay la kulanto dhammaadka tijaabooyinka muhiimka ah, mustaqbalkeeduna waa "la hubo," ayuu yiri Littlejohn.
Waxaa laga yaabaa inaad jeceshahay inaad akhriso: CAR T Qiimaha daawaynta unug ee Shiinaha
"Litifilimab waxaa markii hore lagu bartay bukaannada lupus-ka maqaarka, wadarta guud ee 132," ayuu yiri Littlejohn. "Waxay heleen waxay ahayd inay la kulantay dhibcaha ugu dambeeya ee hoos u dhaca dhibcaha CLASI ee maqaarka ee usbuuca 16."
Intaa waxaa dheer, daawadu waxay ku guulaysatay inay yarayso tirada kala-goysyada ee cudurada firfircoon, sida uu sheegay Littlejohn.
Ugu dambeyntii, obinutuzumab waxay la kulantay barta ugu dambeysa ee bukaannada qaba lupus nephritis, ayuu yiri Littlejohn.
